Alteration of Serum levels of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), C-reactive protein (CRP), gastrin (GAS) and motilin (MTL) after treatment in the Helicobacter pylori-positive gastric ulcer

Serum levels of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), C-reactive protein (CRP), gastrin (GAS) and motilin (MTL)

  • Yunxiang Chu Department of Gastroenterology, Emergency General Hospital, Beijing 100028, China
  • Lin Jin Department of Gastroenterology, Emergency General Hospital, No. 29, Xibahe Nanli, Chaoyang District, Beijing 100028, China
  • Yan Weng Department of Gastroenterology, Emergency General Hospital, Beijing 100028, China
  • Xiaochuan Liu Department of Gastroenterology, Emergency General Hospital, Beijing 100028, China
DOI: https://doi.org/10.5937/jomb0-55373
Keywords: Serum levels of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), C-reactive protein (CRP), gastrin (GAS) and motilin (MTL) ,Helicobacter pylori, Gastric ulcer, Probiotics, Quadruple therapy, Inflammation, Intestinal flora

Abstract


Aim:This study aimed to explore the clinical efficacy of probiotics plus quadruple therapy on Serum levels of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), C-reactive protein (CRP), gastrin (GAS) and motilin (MTL)  in treating Helicobacter pylori (Hp)-positive gastric ulcer (GU).

Methods:One hundred and twenty-four patients with Hp-positive GU treated in our hospital from January 2021 to January 2024 were randomly separated into control group and observation group. The former received conventional quadruple therapy, and the latter received tetralogy of viable bifidobacterium tablets combined with conventional quadruple therapy. The clinical efficacy, Hp eradication rate, levels of inflammatory cytokines and gastrointestinal hormone, incidence of adverse reactions along with quality of life were compared in 2 groups.

Results:The total effective rate of the observation group was 96.77%, higher than that of the control group (82.25%). The Hp eradication rate in the observation group was higher than the control group. After therapy, IL-6, TNF-α and CRP levels were declined in 2 groups, and those in the observation group presented lower as comparing with the control group. After therapy, MLT level was elevated while GAS level was declined in 2 groups, and the improvements of MLT and GAS levels in the observation group were more significant as comparing with the control group. The incidence of diarrhea in the observation group was lower than that in the control group, and there was no difference in the incidence of nausea and abdominal distension between 2 groups.

Conclusion:After therapy, physiological function, physical function, emotional function, body pain, general health, mental health, vitality and social function scores were elevated in 2 groups, and those in the observation group presented higher as comparing with the control group. Probiotics combined with quadruple therapy is effective and safe in the treatment of Hp-positive GU, which can promote the Hp eradication rate, improve the inflammation response and gastrointestinal hormone levels, maintain the balance of intestinal flora and promote the quality of life of patients.

References

1. Gong H, Zhao N, Zhu C, Luo L, Liu S (2024) Treatment of gastric ulcer, traditional Chinese medicine may be a better choice. J Ethnopharmacol 324: 117793.
2. Malfertheiner P, Camargo MC, El-Omar E, Liou JM, Peek R, Schulz C, Smith SI, Suerbaum S (2023) Helicobacter pylori infection. Nat Rev Dis Primers 9: 19.
3. Lee YC, Dore MP, Graham DY (2022) Diagnosis and Treatment of Helicobacter pylori Infection. Annu Rev Med 73: 183-195.
4. Sousa C, Ferreira R, Azevedo NF, Oleastro M, Azeredo J, Figueiredo C, Melo LDR (2022) Helicobacter pylori infection: from standard to alternative treatment strategies. Crit Rev Microbiol 48: 376-396.
5. Hwang JJ, Lee DH, Lee AR, Yoon H, Shin CM, Park YS, Kim N (2015) Characteristics of gastric cancer in peptic ulcer patients with Helicobacter pylori infection. World J Gastroenterol 21: 4954-4960.
6. Zhou L, Lu H, Song Z, Lyu B, Chen Y, Wang J, Xia J, Zhao Z (2022) 2022 Chinese national clinical practice guideline on Helicobacter pylori eradication treatment. Chin Med J (Engl) 135: 2899-2910.
7. Chen L, Xu W, Lee A, He J, Huang B, Zheng W, Su T, Lai S, Long Y, Chu H, Chen Y, Wang L, Wang K, Si J, Chen S (2018) The impact of Helicobacter pylori infection, eradication therapy and probiotic supplementation on gut microenvironment homeostasis: An open-label, randomized clinical trial. EBioMedicine 35: 87-96.
8. Yao G, Fan X, Lu D (2023) Efficacy and safety of probiotic-supplemented bismuth quadruple therapy for the treatment of Helicobacter pylori infection: a systematic review and meta-analysis. J Int Med Res 51: 3000605231203841.
9. Nabavi-Rad A, Sadeghi A, Asadzadeh Aghdaei H, Yadegar A, Smith SM, Zali MR (2022) The double-edged sword of probiotic supplementation on gut microbiota structure in Helicobacter pylori management. Gut Microbes 14: 2108655.
10. Goderska K, Agudo Pena S, Alarcon T (2018) Helicobacter pylori treatment: antibiotics or probiotics. Appl Microbiol Biotechnol 102: 1-7.
11. Qureshi N, Li P, Gu Q (2019) Probiotic therapy in Helicobacter pylori infection: a potential strategy against a serious pathogen? Appl Microbiol Biotechnol 103: 1573-1588.
12. Bai X, Zhu M, He Y, Wang T, Tian D, Shu J (2022) The impacts of probiotics in eradication therapy of Helicobacter pylori. Archives of microbiology 204: 692.
13. He C, Xie Y, Zhu Y, Zhuang K, Huo L, Yu Y, Guo Q, Shu X, Xiong Z, Zhang Z, Lyu B, Lu N (2022) Probiotics modulate gastrointestinal microbiota after Helicobacter pylori eradication: A multicenter randomized double-blind placebo-controlled trial. Front Immunol 13: 1033063.
14. Teo BJX, Koh JSB, Jiang L, Allen JC, Yeo SJ, Howe TS (2019) Association of the 36-Item Short Form Health Survey Physical Component Summary Score With Patient Satisfaction and Improvement 2 Years After Total Knee Arthroplasty. JAMA Netw Open 2: e190062.
15. Shih IC, Chen HC, Chuang CH (2023) An Unusual Cause of Refractory Gastric Ulcer. Gastroenterology 164: 1059-1061.
16. van Zanten SV, van der Knoop B (2008) Gastric ulcer treatment: cure of Helicobacter pylori infection without subsequent acid-suppressive therapy: is it effective? Eur J Gastroenterol Hepatol 20: 489-491.
17. Li WQ, Zhang JY, Ma JL, Li ZX, Zhang L, Zhang Y, Guo Y, Zhou T, Li JY, Shen L, Liu WD, Han ZX, Blot WJ, Gail MH, Pan KF, You WC (2019) Effects of Helicobacter pylori treatment and vitamin and garlic supplementation on gastric cancer incidence and mortality: follow-up of a randomized intervention trial. Bmj 366: l5016.
18. Medakina I, Tsapkova L, Polyakova V, Nikolaev S, Yanova T, Dekhnich N, Khatkov I, Bordin D, Bodunova N (2023) Helicobacter pylori Antibiotic Resistance: Molecular Basis and Diagnostic Methods. Int J Mol Sci 24.
19. Sun Q, Yuan C, Zhou S, Lu J, Zeng M, Cai X, Song H (2023) Helicobacter pylori infection: a dynamic process from diagnosis to treatment. Front Cell Infect Microbiol 13: 1257817.
20. Shah N, Gossman W (2024) Omeprazole. In: StatPearls. StatPearls Publishing
Copyright © 2024, StatPearls Publishing LLC., Treasure Island (FL) ineligible companies. Disclosure: William Gossman declares no relevant financial relationships with ineligible companies.,
21. Yeo YH, Shiu SI, Ho HJ, Zou B, Lin JT, Wu MS, Liou JM, Wu CY (2018) First-line Helicobacter pylori eradication therapies in countries with high and low clarithromycin resistance: a systematic review and network meta-analysis. Gut 67: 20-27.
22. Yeh JA, Huang HK, Chou AL, Lin HJ, Feng CL, Kuo CJ, Lai CH (2024) Helicobacter pylori eradication with high-dose proton pump inhibitor-amoxicillin dual therapy: A systematic review and meta-analysis. Int J Antimicrob Agents 63: 107159.
23. Suo B, Tian X, Zhang H, Lu H, Li C, Zhang Y, Ren X, Yao X, Zhou L, Song Z (2023) Bismuth, esomeprazole, metronidazole, and minocycline or tetracycline as a first-line regimen for Helicobacter pylori eradication: A randomized controlled trial. Chin Med J (Engl) 136: 933-940.
24. Poonyam P, Chotivitayatarakorn P, Vilaichone RK (2019) High Effective of 14-Day High-Dose PPI- Bismuth-Containing Quadruple Therapy with Probiotics Supplement for Helicobacter Pylori Eradication: A Double Blinded-Randomized Placebo-Controlled Study. Asian Pac J Cancer Prev 20: 2859-2864.
25. Hamilton-Miller JM (2003) The role of probiotics in the treatment and prevention of Helicobacter pylori infection. Int J Antimicrob Agents 22: 360-366.
26. Jiang X, Xu C, Liu B, Chen P, Xu Q, Zhang L (2023) Efficacy and safety of bifidobacterium quadruple viable tablets in the treatment of Helicobacter pylori-infected peptic ulcer or gastritis patients: a systematic review and meta-analysis. BMC infectious diseases 23: 313.
27. Viazis N, Argyriou K, Kotzampassi K, Christodoulou DK, Apostolopoulos P, Georgopoulos SD, Liatsos C, Giouleme O, Koustenis K, Veretanos C, Stogiannou D, Moutzoukis M, Poutakidis C, Mylonas, II, Tseti I, Mantzaris GJ (2022) A Four-Probiotics Regimen Combined with A Standard Helicobacter pylori-Eradication Treatment Reduces Side Effects and Increases Eradication Rates. Nutrients 14.
28. Noto JM, Piazuelo MB, Shah SC, Romero-Gallo J, Hart JL, Di C, Carmichael JD, Delgado AG, Halvorson AE, Greevy RA, Wroblewski LE, Sharma A, Newton AB, Allaman MM, Wilson KT, Washington MK, Calcutt MW, Schey KL, Cummings BP, Flynn CR, Zackular JP, Peek RM, Jr. (2022) Iron deficiency linked to altered bile acid metabolism promotes Helicobacter pylori-induced inflammation-driven gastric carcinogenesis. J Clin Invest 132.
29. Yu B, de Vos D, Guo X, Peng S, Xie W, Peppelenbosch MP, Fu Y, Fuhler GM (2024) IL-6 facilitates cross-talk between epithelial cells and tumor- associated macrophages in Helicobacter pylori-linked gastric carcinogenesis. Neoplasia (New York, NY) 50: 100981.
30. Watanabe J, Kotani K (2022) The effect of Helicobacter pylori eradication on C-reactive protein: results from a meta-analysis. Archives of medical science : AMS 18: 958-964.
31. Yu HJ, Liu W, Chang Z, Shen H, He LJ, Wang SS, Liu L, Jiang YY, Xu GT, An MM, Zhang JD (2015) Probiotic BIFICO cocktail ameliorates Helicobacter pylori induced gastritis. World J Gastroenterol 21: 6561-6571.
32. Li Z, Peng C, Sun Y, Zhang T, Feng C, Zhang W, Huang T, Yao G, Zhang H, He Q (2024) Both viable Bifidobacterium longum subsp. infantis B8762 and heat-killed cells alleviate the intestinal inflammation of DSS-induced IBD rats. Microbiol Spectr 12: e0350923.
33. Franceschi F, Genta RM, Sepulveda AR (2002) Gastric mucosa: long-term outcome after cure of Helicobacter pylori infection. Journal of gastroenterology 37 Suppl 13: 17-23.
34. Feng X, Shi XMY (2020) Correlations of recurrence of gastric cancer in patients after radical surgery with serum gastrointestinal hormones, vascular endothelial growth factors and serum anti-helicobacter pylori IgG antibody. J buon 25: 1476-1481.
35. Zhou H, Li Y, Lu W (2024) Treatment Effects of Bifidobacterium Quadruple Viable Tablets Combined With Quadruple Therapy on Helicobacter Pylori-Infected Peptic Ulcer in Children. Clinical pediatrics: 99228241248717.
36. Russo F, Linsalata M, Orlando A (2014) Probiotics against neoplastic transformation of gastric mucosa: effects on cell proliferation and polyamine metabolism. World J Gastroenterol 20: 13258-13272.
37. Niu ZY, Li SZ, Shi YY, Xue Y (2021) Effect of gastric microbiota on quadruple Helicobacter pylori eradication therapy containing bismuth. World J Gastroenterol 27: 3913-3924.
38. Samara J, Moossavi S, Alshaikh B, Ortega VA, Pettersen VK, Ferdous T, Hoops SL, Soraisham A, Vayalumkal J, Dersch-Mills D, Gerber JS, Mukhopadhyay S, Puopolo K, Tompkins TA, Knights D, Walter J, Amin H, Arrieta MC (2022) Supplementation with a probiotic mixture accelerates gut microbiome maturation and reduces intestinal inflammation in extremely preterm infants. Cell Host Microbe 30: 696-711.e695.
39. Wallace C, Gordon M, Sinopoulou V, Akobeng AK (2023) Probiotics for management of functional abdominal pain disorders in children. Cochrane Database Syst Rev 2: Cd012849.
40. Luo C, Peng S, Li M, Ao X, Liu Z (2022) The Efficacy and Safety of Probiotics for Allergic Rhinitis: A Systematic Review and Meta-Analysis. Front Immunol 13: 848279.
Published
2025/05/04
Issue
Vol. 44 No. 7 (2025): Journal of Medical Biochemistry
Section
Original paper

Copyright (c) 2025 Yunxiang Chu, Lin Jin, Yan Weng, Xiaochuan Liu

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.